Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
Trending on Bing
Mexico elects 1st woman pres
Calls on Supreme Court
Pancreatic cancer diagnosis
Announces farewell tour
Mass. teacher put on leave
Says Trump should be jailed
Clips power line, several hurt
Sells 10% stake for $1.05B
Murder charges dropped
CA braces for extreme heat
Blue Lagoon reopens
Trial ‘very hard’ on wife
Late matches are 'not healthy'
Pokes fun at NFL's Butker
Card fetches $2.928 million
Released by Commanders
Wisc. prison warden quits
Rescheduled for June 5
Revised Skydance offer
Pittsburgh shooting kills 2
GameStop shares surge
Solidarity visit to Israel
Federal gun trial begins
To extend production cuts
Detroit train station restored
157th NHRA victory
Hikes prices of premium plans
Airlines raise profit outlook
NASCAR Cup series win
Pres Smith on AI deepfakes
Launches new AI chips
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, OpenAI
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Intelligence.
Sanofi partners with OpenAI: here’s how it will mitigate AI related risks
Sanofi SA (EPA: SAN) is in focus today after teaming up with OpenAI to deploy artificial intelligence for drug development. What’s in it for Sanofi? Working with the AI company will help Sanofi “go to market faster with our drugs” and address the unmet patient needs,
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects. Also Read: Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings.
France's Sanofi Partners With OpenAI to Accelerate Drug Development
By Mauro Orru French pharmaceutical company Sanofi is partnering with Sam Altman's OpenAI and AI pharma company Formation Bio to expedite the development
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationParis, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi,
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data,
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
Sanofi SNY announced that it has entered into a first-in-class artificial intelligence (AI) collaboration with Formation Bio and OpenAI to build AI-powered software to expedite the development of drugs.
Sanofi, OpenAI To Build AI Software To Boost Drug Development
French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI
4d
OpenAI partners with The Atlantic and The Verge publisher Vox Media
OpenAI will also get licensed content and data that it can use to train its large language models (LLMs) and multimedia AI models.
Yahoo
9d
This Week in AI: OpenAI and publishers are partners of convenience
Keeping up with an industry as fast-moving as AI is a tall order. So until an AI can do it for you, here’s a handy roundup of ...
devdiscourse
13d
Health Sector Highlights: FDA Bird Flu Tests, AI Drug Development, and Diabetes Drug Approvals
Breaking health news includes the FDA testing bird flu in milk samples across 17 states, Sanofi’s partnership with OpenAI for AI-driven drug development, and Eli Lilly's diabetes drug tirzepatide ...
11d
InnovationRx: Under 30 Alum Raises $35 Million For Virtual Addiction Treatment
Immunology: AltruBio raised a $225 million Series B led by BVF Partners LP as the biotech startup advances Phase 2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback